v3.25.3
Fair value measurement (Tables)
9 Months Ended
Sep. 30, 2025
Fair value measurement  
Schedule of assets and liabilities measured at fair value on recurring basis

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

   

Quoted prices
in active
markets
(Level 1)

   

Significant
other
observable
inputs
(Level 2)

   

Significant
unobservable
inputs
(Level 3)

   

Total

   

Classification in Consolidated
balance sheets

​

​

​

(in thousands)

​

​

Balance at December 31, 2024

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Assets:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Cash and cash equivalents

​

$

158,930

​

$

—

​

$

—

​

$

158,930

​

Cash and cash equivalents

Restricted cash

​

​

1,399

​

​

—

​

​

—

​

​

1,399

​

Other non-current assets

Total assets

​

$

160,329

​

$

—

​

$

—

​

$

160,329

​

​

Liabilities:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Contingent consideration

​

​

—

​

​

—

​

​

10,860

​

​

10,860

​

Contingent consideration

Consideration for post-acquisition services

​

​

—

​

​

—

​

​

370

​

​

370

​

Other non-current liabilities

Total liabilities

​

$

—

​

$

—

​

$

11,230

​

$

11,230

​

​

Balance at September 30, 2025

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Assets:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Cash and cash equivalents

​

$

597,056

​

$

—

​

$

—

​

$

597,056

​

Cash and cash equivalents

Restricted cash

​

​

1,493

​

​

—

​

​

—

​

​

1,493

​

Other non-current assets

Total assets

​

$

598,549

​

$

—

​

$

—

​

$

598,549

​

​

Liabilities:

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Liability related to pre-funded warrants

​

​

—

​

​

30,722

​

​

—

​

​

30,722

​

Liability related to pre-funded warrants

Contingent consideration

​

​

—

​

​

—

​

​

17,754

​

​

17,754

​

Contingent consideration

Consideration for post-acquisition services

​

​

—

​

​

—

​

​

605

​

​

605

​

Other non-current liabilities

Total liabilities

​

$

—

​

$

30,722

​

$

18,359

​

$

49,081

​

​

Schedule of changes in fair value of contingent consideration

​

​

​

​

​

​

​

Amount of

​

​

contingent

​

​

consideration

​

   

2025

​

​

(in thousands)

Balance at December 31, 2024

​

$

10,860

Unrealized change in fair value (presented within research and development expenses)

​

​

5,293

Currency translation effects

​

​

1,601

Balance at September 30, 2025

​

$

17,754

Schedule of changes in fair value of pre funded warrants

​

​

​

​

​

Liability related

​

to pre-funded

​

warrants

​

2025

​

(in thousands)

Balance at December 31, 2024

$

—

Issuance of pre-funded warrants in connection with follow-on public offering

​

25,000

Unrealized change in fair value

​

5,722

Balance at September 30, 2025

$

30,722